Author:
Nolan Patrick J.,Jain Raksha,Cohen Leah,Finklea James D.,Smith Tiffeny T.
Funder
University of Texas Southwestern Medical Center
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference24 articles.
1. Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam;Atkin;Infect Drug Resist,2018
2. Avycaz™; GlaxoSmithKline manufacturing S.p.A., Verona, Italy. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005,s006lbl.pdf.
3. Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates;Buehrle;Antimicrob Agents Chemother,2016
4. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients;Chalhoub;J Antimicrob Chemother,2015
5. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 28th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献